Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

89
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
89
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

441
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
441
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

114
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
114
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

99
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
99
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

576
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
576
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

207
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
207

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment.

Health affairs scholar·2026
Same author

Wearable-Measured Physical Activity Goal Adherence and Body Composition Change in a 12-Month mHealth Weight Loss Trial.

Sensors (Basel, Switzerland)·2026
Same author

Diabetes educational interventions in care homes: a scoping review.

BMC medical education·2026
Same author

Research Code Sharing in Support of Gold Standard Science.

Journal of diabetes science and technology·2026
Same author

Trajectories of Adherence to Study-Prescribed Physical Activity Goals in a mHealth Weight Loss Intervention.

Sensors (Basel, Switzerland)·2025
Same author

Natural Language Processing for Automated Extraction of Continuous Glucose Monitoring Data.

Diabetes care·2025

Related Experiment Video

Updated: Nov 5, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.0K

mHealth Technology and CVD Risk Reduction.

Maan Isabella Cajita1, Yaguang Zheng2, Jacob Kigo Kariuki3

  • 1College of Nursing, University of Illinois at Chicago, 845 S. Damen Ave., Room 756, Chicago, IL, USA. mcajit2@uic.edu.

Current Atherosclerosis Reports
|May 13, 2021
PubMed
Summary

Mobile health (mHealth) interventions show potential for reducing cardiovascular disease (CVD) risk factors. However, evidence for their effectiveness is mixed, with varying results across weight loss, physical activity, smoking cessation, diabetes, and hypertension interventions.

Keywords:
CVD risk factorsCardiovascular diseasePhysical activitySmokingWeight lossmHealth

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Assessing the Accuracy of Fitness Smartwatch Data for Cardiovascular and Physical Activity Monitoring: A Validation Study in Digital Health
05:51

Assessing the Accuracy of Fitness Smartwatch Data for Cardiovascular and Physical Activity Monitoring: A Validation Study in Digital Health

Published on: February 21, 2025

802

Related Experiment Videos

Last Updated: Nov 5, 2025

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

12.0K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.8K
Assessing the Accuracy of Fitness Smartwatch Data for Cardiovascular and Physical Activity Monitoring: A Validation Study in Digital Health
05:51

Assessing the Accuracy of Fitness Smartwatch Data for Cardiovascular and Physical Activity Monitoring: A Validation Study in Digital Health

Published on: February 21, 2025

802

Area of Science:

  • Digital health
  • Cardiovascular disease prevention
  • Public health interventions

Background:

  • Cardiovascular disease (CVD) remains a leading cause of mortality globally.
  • Lifestyle modifications are crucial for managing CVD risk factors.
  • Mobile health (mHealth) offers a scalable platform for health interventions.

Purpose of the Study:

  • To systematically review mHealth interventions aimed at reducing CVD risk factors.
  • To evaluate the efficacy of these digital health strategies.

Main Methods:

  • A comprehensive literature search identified 50 relevant articles.
  • Interventions focused on weight loss, physical activity, smoking cessation, diabetes management (HbA1c), and hypertension (blood pressure).
  • Included randomized controlled trials (RCTs) and other study designs.

Main Results:

  • mHealth interventions demonstrated varied success: 4/9 for weight loss, 4/7 for physical activity, 4/8 for smoking cessation, 5/10 for HbA1c reduction, and 3/9 for blood pressure reduction.
  • Most interventions targeted single CVD risk factors, with a few addressing multiple factors.
  • Evidence for efficacy in mitigating cardiovascular risk is heterogeneous.

Conclusions:

  • mHealth interventions are increasingly being developed to target CVD risk factors.
  • Despite promising potential, the current evidence base shows inconsistent efficacy.
  • Further research is needed to optimize mHealth strategies for cardiovascular risk reduction.